Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide

被引：0
作者：
Aseem Anand
Michael J. Morris
Steven M. Larson
David Minarik
Andreas Josefsson
John T. Helgstrand
Peter S. Oturai
Lars Edenbrandt
Martin Andreas Røder
Anders Bjartell
机构：
[1] Lund University,Department of Translational Medicine, Division of Urological Cancers
[2] Memorial Sloan Kettering Cancer Center,Department of Medicine
[3] Weil Cornell Medical College,Department of Radiology
[4] Memorial Sloan Kettering Cancer Center,Department of Radiation Physics, Skåne University Hospital
[5] Lund University,Department of Urology, Institute of Clinical Sciences
[6] Sahlgrenska Academy,Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet
[7] University of Copenhagen,Department of Clinical Physiology, Nuclear Medicine and PET
[8] Copenhagen University Hospital,Department of Nuclear Medicine
[9] Skåne University Hospital,Department of Urology
[10] Skåne University Hospital,undefined
来源：
EJNMMI Research | / 6卷
关键词：
Bone Scan Index (BSI); Imaging biomarker; Bone scan; Enzalutamide; Metastatic castration-resistant prostate cancer (mCRPC);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
    Salvi, Samanta
    Casadio, Valentina
    Conteduca, Vincenza
    Lolli, Cristian
    Gurioli, Giorgia
    Martignano, Filippo
    Schepisi, Giuseppe
    Testoni, Sara
    Scarpi, Emanuela
    Amadori, Dino
    Calistri, Daniele
    Attard, Gerhardt
    De Giorgi, Ugo
    ONCOTARGET, 2016, 7 (25) : 37839 - 37845
  • [42] ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis
    Schlack, Katrin
    Krabbe, Laura -Maria
    Rahbar, Kambiz
    Isenberg, Karoline
    Semjonow, Axel
    Schrader, Andres Jan
    Boegemann, Martin
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (10) : 3986 - 3999
  • [43] Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer
    Kato, Haruo
    Furuya, Yosuke
    Miyazawa, Yoshiyuki
    Miyao, Takeshi
    Syuto, Takahiro
    Nomura, Masashi
    Sekine, Yoshitaka
    Koike, Hidekazu
    Matsui, Hiroshi
    Shibata, Yasuhiro
    Ito, Kazuto
    Suzuki, Kazuhiro
    ANTICANCER RESEARCH, 2016, 36 (11) : 6141 - 6149
  • [44] Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression
    Becker, Daniel J.
    Iyengar, Arjun D.
    Punekar, Salman R.
    Ng, Jason
    Zaman, Anika
    Loeb, Stacy
    Becker, Kevin D.
    Makarov, Danil
    ANTICANCER RESEARCH, 2019, 39 (05) : 2467 - 2473
  • [45] Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide
    Modena, Alessandra
    Ciccarese, Chiara
    Fantinel, Emanuela
    Bimbatti, Davide
    Tortora, Giampaolo
    Massari, Francesco
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (09) : 1037 - 1048
  • [46] Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer
    Zhang, Tian
    Zhu, Jason
    George, Daniel J.
    Armstrong, Andrew J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (04) : 473 - 485
  • [47] Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer
    Chen, William S.
    Aggarwal, Rahul
    Zhang, Li
    Zhao, Shuang G.
    Thomas, George, V
    Beer, Tomasz M.
    Quigley, David A.
    Foye, Adam
    Playdle, Denise
    Huang, Jiaoti
    Lloyd, Paul
    Lu, Eric
    Sun, Duanchen
    Guan, Xiangnan
    Rettig, Matthew
    Gleave, Martin
    Evans, Christopher P.
    Youngren, Jack
    True, Lawrence
    Lara, Primo N.
    Kothari, Vishal
    Xia, Zheng
    Chi, Kim N.
    Reiter, Robert E.
    Maher, Christopher A.
    Feng, Felix Y.
    Small, Eric J.
    Alumkal, Joshi J.
    EUROPEAN UROLOGY, 2019, 76 (05) : 562 - 571
  • [48] Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
    Lin, Jianqing
    Elkon, Jacob
    Ricart, Brittany
    Palmer, Erica
    Zevallos-Delgado, Christian
    Noonepalle, Satish
    Burgess, Brooke
    Siegel, Robert
    Ma, Yan
    Villagra, Alejandro
    ONCOLOGIST, 2021, 26 (12) : E2136 - E2142
  • [49] High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients
    Hsieh, Yu-Ting
    Chiang, Bing-Juin
    Wu, Chia-Chang
    Liao, Chun-Hou
    Lin, Chia-Da
    Chen, Chung-Hsin
    CANCERS, 2021, 13 (16)
  • [50] Lack of interaction between enzalutamide and warfarin in a metastatic castration-resistant prostate cancer patient
    Casserly, Elizabeth A.
    Rogers, Sara E.
    Keisner, Sidney V.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (01) : 68 - 70
12345